SCHEMBL3130177

SCHEMBL3130177

Cc1c(C(=O)NN)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 16/20 1.00
CNR1 P21554 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907714 0.95 CNR2 (0.91) CNR2CNR1
SCHEMBL30961589 0.93 CNR2 (0.88) CNR2CNR1
SCHEMBL1009687 0.93 CNR2 (0.87) CNR2CNR1
SCHEMBL4903857 0.90 CNR2 (0.82) CNR2CNR1
SCHEMBL2734336 0.89 CNR2 (0.83) CNR2CNR1
Hydrochloric Acid SCHEMBL4916328 0.89 CNR2 (0.80) CNR2CNR1
SCHEMBL16475874 0.89 CNR2 (1.00) CNR2CNR1
SCHEMBL4911796 0.88 CNR2 (0.81) CNR2CNR1
SCHEMBL4462537 0.88 CNR2 (0.79) CNR2CNR1
SCHEMBL925525 0.88 CNR2 (0.79) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773783-B1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI AVENTIS (FR) 2010-05-05 EP claimed
US-7462632-B2 Method for the preparation of N-piperidino-1, 5-diphenylpyrazole-3-carboxamide derivatives SANOFI-AVENTIS (FR) 2008-12-09 US claimed
US-20080119653-A1 METHOD FOR THE PREPARATION OF N-PIPERIDINO-1, 5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2008-05-22 US claimed
EP-1773783-A1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES Sanofi-Aventis (FR) 2007-04-18 EP claimed
WO-2006021652-A1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2006-03-02 WO claimed
WO-2025040089-A1 NOVEL HETEROCYCLIC COMPOUND FOR SELECTIVELY REGULATING CANNABINOID CB1 FUNCTION 德睿智药(苏州)新药研发有限公司 2025-02-27 WO disclosed
EP-1773783-B1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI AVENTIS (FR) 2010-05-05 EP disclosed
US-20100076197-A1 PROCESS FOR RIMONABANT HETERO DRUGS LIMITED (IN) 2010-03-25 US disclosed
US-7632852-B2 (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2009-12-15 US disclosed
WO-2009109222-A1 PROCESS FOR THE PREPARATION OF RIMONABANT MAPRIMED, S. A. (AR) 2009-09-11 WO disclosed
EP-2061783-A2 IMPROVED PROCESS FOR RIMONABANT Hetero Drugs Limited (IN) 2009-05-27 EP disclosed
US-7462632-B2 Method for the preparation of N-piperidino-1, 5-diphenylpyrazole-3-carboxamide derivatives SANOFI-AVENTIS (FR) 2008-12-09 US disclosed
US-20080119653-A1 METHOD FOR THE PREPARATION OF N-PIPERIDINO-1, 5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2008-05-22 US disclosed
US-20080119653-A1 METHOD FOR THE PREPARATION OF N-PIPERIDINO-1, 5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2008-05-22 US disclosed
WO-2008032330-A2 IMPROVED PROCESS FOR RIMONABANT HETERO DRUGS LIMITED (IN) 2008-03-20 WO disclosed
US-20080039510-A1 (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2008-02-14 US disclosed
EP-1853595-A1 (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2007-11-14 EP disclosed
EP-1773783-A1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006087480-A1 (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2006-08-24 WO disclosed
WO-2006021652-A1 METHOD FOR PREPARING N-PIPERIDINO-1,5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039510-A1 (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS DHFR, DPYD, THPO CNR2 933/4885CNR1 767/4885
US-20100076197-A1 PROCESS FOR RIMONABANT CNR1, CNR2, AADAT CNR2 2/4885CNR1 1/4885
US-20080119653-A1 METHOD FOR THE PREPARATION OF N-PIPERIDINO-1, 5-DIPHENYLPYRAZOLE-3-CARBOXAMIDE DERIVATIVES HRH2, NUDT1, P2RY4 CNR2 220/4885CNR1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.